Evotec AG has announced that Boehringer Ingelheim has extended the scope of its collaboration with Evotec. In addition to the substantial discovery programme to jointly identify and develop therapeutics acting on G-Protein Coupled Receptors.
Boehringer research sites in Biberach (Germany) and Laval (Canada) will now collaborate with Evotec under a fee-for-service agreement.
For selected Boehringer target proteins, Evotec will apply its skills in biochemical and cellular assay development as well as in ultra-high-throughput screening using its proprietary FCS+plus detection platform to rapidly and accurately identify promising hit molecules from Boehringer's and Evotec's compound libraries. Active compounds will be further progressed by Boehringer to develop treatments for different diseases.
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, commented, "We are extremely delighted to further expand our collaboration with Boehringer Ingelheim. Boehringer is a successful pharmaceutical company which places significant emphasis on innovative approaches to drug discovery."
"The fact that they have chosen Evotec as a partner for assay development and screening services is a strong endorsement of the high quality results we deliver in our ongoing collaboration in the field of drug discovery."
Professor Mikael Dolsten, Head of Corporate Division Pharma Research/Discovery, Boehringer Ingelheim GmbH, said, "Evotec has a strong track record in performing uHTS screens and handling large compound pools in complex assays."
"Evotec's proprietary detection technology also offers sensitive and robust systems for hit identification. These skills together with the experience we have made in our ongoing collaboration have convinced us that Evotec is the ideal partner for our drug finding programmes."